Close Menu

NEW YORK (360Dx) — The US Food and Drug Administration on Friday granted 510(k) clearance to an influenza A and B immunoassay from Quidel.

The test runs on the firm's next-generation immunoassay platform, Sofia 2, which was cleared last month with an assay for respiratory syncytial virus.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.